Global Live Biotherapeutics Market set for rapid growth, reaching US$ 422.9 Mn by 2034 with 14% CAGR. Rising demand for microbiome therapies driving expansion. Key drivers include chronic disease prevalence, microbiome research advances, regulatory environment, and investments from industry players. Leading companies include Ferring Pharmaceuticals, Seres Therapeutics, 4D Pharma, Finch Therapeutics, and Vedanta Biosciences.

The Global Live Biotherapeutics Market was valued at US$105.5 million in 2023 and is projected to grow at a CAGR of 14% from 2024 to 2034, surpassing US$422.9 million by 2034. This growth is driven by a rising interest in microbiome-based therapies for chronic and infectious diseases. Live biotherapeutics are living microorganisms used to prevent, treat, or cure diseases, and they undergo rigorous testing for safety and effectiveness. The market growth is attributed to the demand for innovative treatments for chronic illnesses, gastrointestinal disorders, and immune system regulation. Key drivers include the prevalence of chronic diseases, advances in microbiome research, supportive regulatory environment, and growing investments and partnerships in the development of live biotherapeutics. Major players in the market include Ferring Pharmaceuticals, Seres Therapeutics, 4D Pharma, Finch Therapeutics, Vedanta Biosciences, and Synthetic Biologics. Regulatory agencies like the FDA and EMA are establishing guidelines for live biotherapeutic products, fostering innovation while ensuring safety and efficacy in the market.